How You Could Double Your Money at Least 6 TIMES This Year

On May 19, iconic growth investor Louis Navellier will reveal how his powerful quant-based stock system could accelerate your wealth and help fund your retirement.

Wed, May 19 at 4:00PM ET
 
 
 
 

5 Stocks With Awful Analyst Earnings Revisions — SOL IFT GLYC RELL VRTX

This week, these five stocks have the worst ratings in Analyst Earnings Revisions, one of the eight Fundamental Categories on Portfolio Grader.

ReneSola Ltd. Sponsored ADR (SOL) develops, manufactures and sells solar wafers, which are thin sheets of crystalline silicon material mainly made by slicing monocrystalline or multicrystalline ingots. SOL gets F’s in Equity and Cash Flow as well. Since January 1, SOL has fallen 18.8%. This is worse than the S&P 500, which has remained flat. For more information, get Portfolio Grader’s complete analysis of SOL stock.

Imperial Holdings, Inc. (IFT) is a specialty finance company with a focus on providing financing for individual life insurance policies and purchasing structured settlements. IFT gets F’s in Earnings Growth, Earnings Momentum, Operating Margin Growth and Sales Growth as well. Since January 1, IFT has fallen 4.8%. The stock’s trailing PE Ratio is 87.30. For more information, get Portfolio Grader’s complete analysis of IFT stock.

GLYC also gets F’s in Equity and Sales Growth. For more information, get Portfolio Grader’s complete analysis of GLYC stock.

Richardson Electronics, Ltd. (RELL) provides engineered solutions and distributes electronic components to the global radio frequency, wireless and power conversion, electron device, security and display systems. RELL also gets F’s in Earnings Growth, Operating Margin Growth and Sales Growth. Shares of the stock have declined 6% since January 1. For more information, get Portfolio Grader’s complete analysis of RELL stock.

Vertex Pharmaceuticals Incorporated (VRTX) is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. VRTX gets F’s in Earnings Momentum, Equity and Sales Growth as well. The price of VRTX is down 7.4% since the first of the year. For more information, get Portfolio Grader’s complete analysis of VRTX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/02/5-stocks-with-awful-analyst-earnings-revisions-sol-ift-glyc-rell-vrtx-sol-ift-glyc/.

©2021 InvestorPlace Media, LLC